{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Appendix 2', 'Regulatory, Ethical, and Study Oversight Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with the following:', '- Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and Council for International Organizations of Medical', 'Sciences (CIOMS) International Ethical Guidelines.', '- Applicable International Council for Harmonisation (ICH) Good Clinical Practice', '(GCP) Guidelines.', '- Applicable laws and regulations.', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant', 'documents (eg, advertisements) must be submitted to an IRB/IEC by the Investigator and', 'reviewed and approved by the IRB/IEC before the study is initiated.', 'Any amendments to the protocol will require IRB/IEC and regulatory authority approval,', 'when applicable, before implementation of changes made to the study design, except for', 'changes necessary to eliminate an immediate hazard to subjects.', 'The Investigator will be responsible for the following:', '- Providing written summaries of the status of the study to the IRB/IEC annually or', 'more frequently in accordance with the requirements, policies, and procedures', 'established by the IRB/IEC.', '- Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures.', '- Providing oversight of the conduct of the study at the study center and adherence', 'to requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the', 'IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all', 'other applicable local regulations.', 'After reading the protocol, each Investigator will sign the protocol signature page and send', 'a copy of the signed page to the Sponsor or representative (Appendix 8). The study will', 'not start at any study center at which the Investigator has not signed the protocol.', 'Financial Disclosure', 'Investigators and sub-Investigators will provide the Sponsor with enough, accurate financial', 'information as requested to allow the Sponsor to submit complete and accurate financial', 'certification or disclosure statements to the appropriate regulatory authorities. Investigators are', 'responsible for providing information on financial interests during the study and for 1 year after', 'completion of the study.', '56']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Insurance', 'The Sponsor has obtained liability insurance, which covers this study as required by local law', 'and/or national regulations and/or ICH guidelines, whichever is applicable. The terms of the', 'insurance will be kept in the study files.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to the subject', 'or his/her legally authorized representative and answer all questions regarding the study.', 'Subjects must be informed that their participation is voluntary. Subjects or their legally', 'authorized representative will be required to sign a statement of informed consent that', 'meets the requirements of 21 Code of Federal Regulations (CFR) 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was obtained', 'before the subject was entered in the study and the date the written consent was obtained.', 'The authorized person obtaining the informed consent must also sign the ICF.', 'Subjects must be re-consented to the most current version of the ICF(s) during their', 'participation in the study.', \"A copy of the ICF(s) must be provided to the subject or the subject's legally authorized\", 'representative.', 'Data Protection', 'Subjects will be assigned a unique identifier by the Sponsor. Any subject records or', 'datasets that are transferred to the Sponsor will contain the identifier only; subject names', 'or any information which would make the subject identifiable will not be transferred.', 'The subject must be informed that his/her personal study-related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the subject.', 'The subject must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'The ICF will incorporate (or, in some cases, be accompanied by a separate document', 'incorporating) wording that complies with relevant data protection and privacy legislation.', 'The Sponsor or its representative will not provide individual genotype results to subjects,', 'any insurance company, any employer, their family members, general physician, or any', 'other third party, unless required to do so by law.', 'Extra precautions are taken to preserve confidentiality and prevent genetic data being', 'linked to the identity of the subject. In exceptional circumstances, however, certain', 'individuals might see both the genetic data and the personal identifiers of a subject. For', 'example, in the case of a medical emergency, the Sponsor or representative physician or', '57']\n\n###\n\n", "completion": "END"}